Who are Early Vasopressors's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): lidocaine + epinephrine 1:100,000, Articaine / EPINEPHrine Cartridge, low-dose epinephrine and tranexamic acid, Lidocaine plus adrenaline.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/early-vasopressors.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Early Vasopressors — Competitive Intelligence Brief

Early Vasopressors (Early Vasopressors) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sympathomimetic vasopressor. Area: Critical Care / Intensive Care Medicine.

phase 3 Sympathomimetic vasopressor Alpha-1 and beta-1 adrenergic receptors Critical Care / Intensive Care Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Early Vasopressors (Early Vasopressors) — Massachusetts General Hospital. Early vasopressors are sympathomimetic agents that increase blood pressure and tissue perfusion by stimulating adrenergic receptors to counteract hypotension in critically ill patients.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Early Vasopressors TARGET	Early Vasopressors	Massachusetts General Hospital	phase 3	Sympathomimetic vasopressor	Alpha-1 and beta-1 adrenergic receptors
lidocaine + epinephrine 1:100,000	lidocaine + epinephrine 1:100,000	Weill Medical College of Cornell University	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels (lidocaine); alpha-1 and beta-1 adrenergic receptors (epinephrine)
Articaine / EPINEPHrine Cartridge	Articaine / EPINEPHrine Cartridge	Universidad de Antioquia	marketed	Local anesthetic with vasopressor	Voltage-gated sodium channels (articaine); alpha-1 and beta-1 adrenergic receptors (epinephrine)
low-dose epinephrine and tranexamic acid	low-dose epinephrine and tranexamic acid	King Abdullah International Medical Research Center	marketed	Combination hemostatic and vasopressor agent	Alpha-1 and beta-1 adrenergic receptors (epinephrine); plasminogen and plasmin (tranexamic acid)
Lidocaine plus adrenaline	Lidocaine plus adrenaline	University of Santiago de Compostela	marketed	Local anesthetic with vasopressor	Voltage-gated sodium channels; alpha-1 and beta-1 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sympathomimetic vasopressor class)

Massachusetts General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Early Vasopressors — Competitive Intelligence Brief. https://druglandscape.com/ci/early-vasopressors. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab